Oppenheimer Maintains Outperform on Amrize, Lowers Price Target to $65

Benzinga · 3d ago
Oppenheimer analyst Bryan Blair maintains Amrize (NYSE:AMRZ) with a Outperform and lowers the price target from $68 to $65.